^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KLB expression

    i
    Other names: KLB, Klotho Beta, Klotho Beta-Like Protein, Beta-Klotho, BetaKlotho, B-Klotho, BKL, Klotho Beta Like
    Entrez ID:
    152831
    6ms
    Serum β-klotho is a potential biomarker for the progression of hepatitis B virus-related liver diseases. (PubMed, J Infect Dev Ctries)
    Serum KLB level is associated with the severity of HBV-related liver diseases and has important diagnostic value for HCC. Therefore, it could be a predictive biomarker for monitoring disease progression.
    Journal
    |
    AFP (Alpha-fetoprotein) • KLB (Klotho Beta)
    |
    KLB expression
    10ms
    The application of mirabilite in traditional Chinese medicine and its chemical constituents, processing methods, pharmacology, toxicology and clinical research. (PubMed, Front Pharmacol)
    In-depth research on its processing methods, active ingredients, quality control, pharmacokinetics, pharmacological and toxicological mechanisms, and standardized clinical application is needed. This paper provides a reference for the application and research of mirabilite in the future.
    Review • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • KLB (Klotho Beta) • LDLR (Low Density Lipoprotein Receptor)
    |
    KLB expression
    1year
    Klotho-beta attenuates Rab8a-mediated exosome regulation and promotes prostate cancer progression. (PubMed, Oncogene)
    Taken together, this study has unveiled the tumor-promoting role of KLB mediated by its regulation on exosomes secretion through a Rab8a-dependent mechanism. These findings could be exploited to develop novel theranostic targets for prostate cancer.
    Journal
    |
    KLB (Klotho Beta)
    |
    KLB expression
    over1year
    Aberrant acetylated modification of FGF21‑KLB signaling contributes to hepatocellular carcinoma metastasis through the β‑catenin pathway. (PubMed, Int J Oncol)
    Furthermore, the results revealed that HDAC3 inhibitor‑mediated acetylated modification led to KLB inactivation, resulting in the blockade of FGF21‑KLB signaling, which further triggered the expression of EMT induction‑related genes in Huh7 cells. In conclusion, the present study demonstrated that aberrant acetylated modification of KLB inhibited FGF21‑KLB signaling, thereby promoting β‑catenin signaling‑driven EMT and HCC metastasis.
    Journal
    |
    FGF19 (Fibroblast growth factor 19) • FGF21 (Fibroblast Growth Factor 21) • KLB (Klotho Beta) • HDAC3 (Histone Deacetylase 3)
    |
    FGF21 overexpression • KLB expression